ISIS 7597

Drug Profile

ISIS 7597

Latest Information Update: 28 May 2001

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 May 2001 No-Development-Reported for Cancer in USA (Unknown route)
  • 21 Jul 1997 A preclinical study has been added to the pharmacodynamics section
  • 03 Jul 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top